Possibilities of using a fixed combination of alogliptin and pioglitazone in patients with type 2 diabetes mellitus in everyday clinical practice
- Authors: Elsukova O.S.1, Nikitina E.A.1, Chuprova A.V.1, Kaysina O.A.1
-
Affiliations:
- Kirov State Medical University
- Issue: Vol 31, No 2 (2024)
- Pages: 99-104
- Section: Original articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/632442
- DOI: https://doi.org/10.18565/pharmateca.2024.2.99-104
- ID: 632442
Cite item
Open Access
Access granted
Abstract
Background. Due to the progressive course of type 2 diabetes mellitus (DM2), not all patients can achieve target levels of carbohydrate metabolism during monotherapy with glucose-lowering drugs.
Objective. Evaluation of the indicators of carbohydrate metabolism in DM2 patients using a fixed combination of alogliptin and pioglitazone in everyday clinical practice.
Methods. 30 DM2 patients aged from 22 to 72 years (mean age – 50.9±11.4 years) were examined. The state of carbohydrate metabolism was assessed by the of glycated hemoglobin (HbA1c), fasting glycemia and postprandial glycemia levels. The studied parameters were recorded initially and over time after 6 months against the background of combination therapy with alogliptin 25 mg/day and pioglitazone 30 mg/day, with addition of metformin at a dose of 2000 mg/day. The development of symptomatic hypoglycemic conditions and severe hypoglycemia was analyzed.
Results. By the end of the follow-up period, an improvement was noted in all indicators of carbohydrate metabolism – HbA1c decreased from 9.0±1.6 to 6.7±0.7% (p<0.001), fasting glycemia – from 9.1±1.7 to 6, 1±0.8 mmol/l (p<0.001), postprandial glycemia – from 10.3±2.3 to 7.8±0.7 mmol/l (p<0.001). No hypoglycemic conditions or severe hypoglycemia were recorded.
Conclusion. The results of the study confirm the effectiveness and safety of the use of fixed combination of alogliptin 25 mg and pioglitazone 30 mg in DM2 patients in everyday clinical practice.
Keywords
Full Text
About the authors
O. S. Elsukova
Kirov State Medical University
Email: nikitinae1991@mail.ru
ORCID iD: 0000-0002-2341-9491
Russian Federation, Kirov
E. A. Nikitina
Kirov State Medical University
Author for correspondence.
Email: nikitinae1991@mail.ru
ORCID iD: 0000-0002-7316-3252
Cand. Sci. (Med.), Associate Professor at the Department of Internal Medicine
Russian Federation, KirovA. V. Chuprova
Kirov State Medical University
Email: nikitinae1991@mail.ru
ORCID iD: 0000-0001-6383-1993
Russian Federation, Kirov
O. A. Kaysina
Kirov State Medical University
Email: nikitinae1991@mail.ru
Russian Federation, Kirov
References
- Дедов И.И., Шестакова М.В., Викулова О.К., и др. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010–2022 гг. Сахарный диабет. 2023;26(2):104–23. [Dedov I.I., Shestakova M.V., Vikulova O.K., et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes Mellitus. 2023;26(2):104–23. doi: 10.14341/DM13035. (In Russ.)]
- Зилов А.В., Фокина А.С., Фадеев В.В. Возможность влияния на многофакторность развития гликемии при сахарном диабете 2 типа комбинированным сахароснижающим препаратом. Русский медицинский журнал. 2022;1:41–5. [Zilov A.V., Fokina A.S., Fadeev V.V. Combined hypoglycemic agent impact on the multifactorial development of glycemia in type 2 diabetes mellitus. Russkii meditsinskii zhurnal. 2022;1:41–5. (In Russ.)]
- Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. М., 2023. [Dedov I.I., Shestakova M.V., Mayorov A.Yu., et al. Standards of specialized diabetes care. Moscow, 2023. (In Russ.)]. doi: 10.14341/DM13042.
- Samson S.L., Vellanki P., Blonde L., et al. American association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 Update. Endocr Pract. 2023;29(5):305–40. doi: 10.1016/j.eprac.2023.02.001.
- Шамхалова М.Ш., Сухарева О.Ю. Ранняя интенсификация терапии сахарного диабета 2 типа и достижение целевого уровня гликогемоглобина HbA1c – необходимые факторы для снижения риска микро- и макрососудистых осложнений. Сахарный диабет. 2023;26(4):343–51. [Shamkhalova M.S., Sukhareva O.Y. Early intensification of therapy for type 2 diabetes mellitus and achievement of the target level of glycohemoglobin HbA1c are necessary factors to reduce the risk of micro- and macrovascular complications. Diabetes Mellitus. 2023;26(4):343–51. (In Russ.)]. doi: 10.14341/DM13079.
- Мкртумян А.М., Белолипецкий Я.А. Тандем алоглиптина и пиоглитазона – новый союз в борьбе с сахарным диабетом 2 типа. Эффективная фармакотерапия. 2021;17(31):18–36. [Mkrtumyan A.M., Belolipetsky Ya.A. The tandem of alogliptin and pioglitazone is a new alliance in the fight against type 2 diabetes. Effective pharmacotherapy. 2021;17(31):18–36. (In Russ.)]. doi: 10.33978/2307-3586-2021-17-31-18-36.
- Triplitt C., Cersosimo E., DeFronzo R.A. Pioglitazone and alogliptin combination therapy in type 2 diabetes: а pathophysiologically sound treatment. Vasc Health Risk Manag. 2010;6:671-690.
- Rosenstock J., Inzucchi S.E., Seufert J., et al. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care. 2010;33(11):2406–408. doi: 10.2337/dc10-0159.
- DeFronzo R.A., Burant C.F., Fleck P., et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 Diabetes. J Clin Endocrinol Metab. 2012;97(5):1615–22.
- Aoki C., Suzuki K., Kuroda H., et al. Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index. Nagoya J Med Sci. 2017;79(1):9–16. doi: 10.18999/nagjms.79.1.9.
Supplementary files
